VA Will Assess Leukemias, Multiple Myeloma as Presumptive Service Conditions

VA Will Assess Leukemias, Multiple Myeloma as Presumptive Service Conditions

In what could be the first conditions added to the new PACT Act, the VA is conducting a scientific review to determine any relationship between three conditions—acute leukemias, chronic leukemias, and multiple myeloma outside of the head and neck—and toxic exposures for servicemembers who deployed to Iraq, Afghanistan, Somalia, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, Uzbekistan, and the entire Southwest Asia theater of operations.

Mast Cell Depletion Affects Prostate Cancer Progression

Better understanding of the cellular immune components underlying aggressive prostate cancer, especially among African American (AA) men who are disproportionately affected by the disease compared with white men, could help improve precision medicine treatment strategies, according to a new study.

Tixagevimab/Cilgavimab Found Effective in Immunocompromised Veterans

The risk of COVID-19 morbidity and mortality is much higher for immunocompromised patients, and, while vaccines have been highly successful at preventing the spread of SARS-CoV-2 and decreasing the likelihood of severe disease in the general population, those who are immunocompromised still face a greater danger for breakthrough infections and persistent viral replication, according to a new study.